David Sinclair resveratrol dosage has become a widely discussed topic following the Harvard biologist's public disclosure of his personal supplementation regimen. Professor Sinclair takes approximately 1,000 mg of resveratrol daily as part of his longevity-focused protocol. However, it is crucial for UK patients and healthcare professionals to understand that this dosage significantly exceeds the UK and EU safety-assessed intake of 150 mg per day for trans-resveratrol. Resveratrol is a polyphenolic compound found in red grapes and berries, marketed for healthy ageing and metabolic support. Whilst preliminary research is intriguing, resveratrol is not licensed as a medicine in the UK and is not recommended by NICE or included in NHS treatment pathways.

What Is Resveratrol and Why Is It Used?

Resveratrol is a naturally occurring polyphenolic compound found predominantly in the skins of red grapes, berries, and certain nuts. It belongs to a class of plant compounds called stilbenes, which are produced by plants as a defence mechanism against environmental stressors such as fungal infection or ultraviolet radiation. In recent years, resveratrol has attracted considerable scientific and public interest due to its potential role in promoting cellular health and longevity.

The compound is thought to potentially influence cellular pathways through several mechanisms, possibly including indirect effects on sirtuins—a family of proteins involved in cellular regulation, DNA repair, and metabolic homeostasis. While sirtuins, particularly SIRT1, have been implicated in processes associated with ageing and age-related diseases, the direct activation of SIRT1 by resveratrol remains scientifically debated. Resveratrol may also possess antioxidant and anti-inflammatory properties, which could theoretically contribute to cardiovascular health and metabolic function. However, it is important to note that much of the evidence derives from laboratory studies in yeast, worms, and rodents, and the translation of these findings to human health remains an area of active investigation.

In the UK, trans-resveratrol is an authorised novel food with specific conditions of use. It is available as a food supplement and is not licensed as a medicine by the Medicines and Healthcare products Regulatory Agency (MHRA). The Food Standards Agency (FSA) typically sets a maximum daily intake of 150 mg for trans-resveratrol in adults, and it is not recommended for children, pregnant women, or breastfeeding mothers. Resveratrol is marketed for general wellness, often with claims related to healthy ageing, cardiovascular support, and metabolic health. Despite its popularity, resveratrol is not currently recommended by NICE or included in standard NHS treatment pathways for any specific medical condition. Individuals considering resveratrol supplementation should be aware that the evidence base for clinical efficacy in humans is still evolving, and it should not replace conventional medical treatments.

David Sinclair's Resveratrol Dosage Recommendations

Professor David Sinclair, a biologist at Harvard Medical School, has been a prominent advocate for resveratrol supplementation as part of a broader longevity-focused lifestyle. In his book Lifespan: Why We Age—and Why We Don't Have To and in various public interviews, Sinclair has disclosed his personal supplementation regimen, which includes resveratrol. He has stated that he takes approximately 1 gram (1,000 mg) of resveratrol daily, typically in the morning mixed with yoghurt or another fat source to potentially enhance absorption, as resveratrol is a lipophilic (fat-soluble) compound, though evidence for enhanced absorption with fat in humans is limited.

Sinclair's rationale for this dosage is based on preclinical research suggesting that resveratrol may influence pathways associated with sirtuins and potentially mimic some of the beneficial effects of caloric restriction, a dietary intervention associated with extended lifespan in animal models. He emphasises that his personal protocol is informed by scientific literature but is not a formal medical recommendation. Sinclair also combines resveratrol with other supplements, including nicotinamide mononucleotide (NMN) and metformin, as part of an integrated approach to healthy ageing.

Important UK regulatory context: It is crucial to understand that Sinclair's dosage of 1,000 mg/day significantly exceeds the UK/EU safety-assessed intake for trans-resveratrol (typically 150 mg/day) and is not recommended without specialist oversight. Additionally, metformin is a prescription-only medicine in the UK and must not be self-sourced for longevity purposes. NMN is a novel food not currently authorised as a food supplement in Great Britain or the EU. Patients should not purchase unregulated products online.

Healthcare professionals in the UK should counsel patients that while Sinclair's work has popularised resveratrol, his regimen does not constitute standard medical advice and should not be adopted without consideration of individual health status, potential drug interactions, and the current evidence base.

Evidence for Resveratrol Dosage in Clinical Studies

Clinical trials investigating resveratrol in humans have employed a wide range of dosages, typically from 150 mg to 2,000 mg daily, depending on the study design and target population. The variability in dosing reflects ongoing uncertainty about the optimal therapeutic dose and the compound's bioavailability, which is known to be relatively low due to rapid metabolism in the liver and intestine.

Several small-scale studies have explored resveratrol's effects on metabolic and cardiovascular parameters. For example, Timmers et al. (2011) reported modest improvements in metabolic parameters using 150 mg daily in obese men, while Poulsen et al. (2013) found no benefit at the same dose. Some trials using doses of 150–500 mg daily have reported modest improvements in markers such as insulin sensitivity, lipid profiles, and endothelial function in individuals with obesity or type 2 diabetes. However, these findings have not been consistently replicated, and effect sizes are generally small. A systematic review published in the European Journal of Clinical Nutrition concluded that while resveratrol may have some beneficial effects on glucose metabolism, the evidence is insufficient to support routine clinical use.

Higher doses, such as 1,000–2,000 mg daily, have been investigated in studies examining cognitive function, inflammation, and cardiovascular health. Wong et al. (2013/2016) studied cerebrovascular and cognitive outcomes in older adults, but results remain inconclusive. Importantly, many clinical trial doses exceed the UK/EU authorised supplemental intake (150 mg/day) and were conducted under trial monitoring conditions. There is currently no official link established by regulatory bodies such as the European Food Safety Authority (EFSA), NICE, or the NHS between resveratrol supplementation and clinically meaningful improvements in longevity or age-related disease prevention in humans.

The lack of standardised dosing recommendations reflects the early stage of resveratrol research in humans. Clinicians should inform patients that while preliminary data are intriguing, resveratrol is not a proven therapeutic agent, and its use should be considered experimental. Patients interested in supplementation should be encouraged to discuss their intentions with their GP, particularly if they have underlying health conditions or are taking other medications.

Safety Considerations and Side Effects of Resveratrol

Resveratrol is generally considered to be well tolerated at commonly used supplemental doses, with most clinical trials reporting few serious adverse events. However, as with any bioactive compound, there are important safety considerations that healthcare professionals and patients should be aware of.

Common side effects reported in clinical studies include:

• Gastrointestinal disturbances such as nausea, diarrhoea, and abdominal discomfort, particularly at higher doses (≥1,000 mg daily)

• Headache and dizziness in some individuals

• Mild allergic reactions, though these are rare

These effects are typically mild and transient, but patients experiencing persistent or severe symptoms should discontinue use and consult their GP.

Drug interactions are a potential concern, though clinical evidence is limited. Resveratrol may have theoretical antiplatelet effects and could potentially increase bleeding risk when combined with anticoagulants (e.g., warfarin, apixaban) or antiplatelet agents (e.g., aspirin, clopidogrel). Patients on warfarin should arrange INR monitoring if starting or stopping resveratrol. Resveratrol undergoes extensive first-pass metabolism primarily via glucuronidation and sulphation (UGT/SULT enzymes). It may also inhibit certain cytochrome P450 enzymes (CYP3A4, CYP2C9, CYP2D6) based on limited human and in vitro data, potentially affecting the metabolism of drugs using these pathways.

Special populations require particular caution. Resveratrol is not recommended for children or adolescents. There is limited safety data in pregnancy and breastfeeding, and resveratrol supplementation is not recommended in these groups. Individuals with hormone-sensitive conditions (e.g., breast cancer, endometriosis) should also exercise caution, as resveratrol has weak oestrogenic activity in some experimental models, although the clinical significance of this is unclear. Patients should stop taking resveratrol 1-2 weeks before scheduled surgery due to potential bleeding risk.

Patients should be advised to purchase supplements from reputable UK or EU manufacturers. Any suspected adverse reactions should be reported to the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk). Patients should seek urgent medical care for signs of severe allergic reaction (e.g., breathing difficulty, facial swelling) and contact NHS 111 for non-urgent advice about side effects.

How to Take Resveratrol: Practical Guidance for UK Users

For individuals in the UK considering resveratrol supplementation, practical guidance can help optimise safety and potential benefit, while acknowledging the limitations of current evidence.

Dosage: Based on UK and EU safety assessments, adults should not exceed 150 mg of trans-resveratrol daily unless under clinical supervision. Higher intakes are outside safety-assessed ranges. While clinical trials have used doses from 150 mg to 1,000 mg daily, David Sinclair's personal regimen of 1,000 mg daily significantly exceeds recommended supplemental intakes and should be considered experimental rather than a standard recommendation. Starting with a lower dose may help minimise gastrointestinal side effects.

Timing and administration: Resveratrol is fat-soluble, and some sources suggest taking it with a meal containing dietary fat, such as yoghurt, nuts, or olive oil, though evidence for enhanced absorption with fat in humans is limited and inconsistent. Some users prefer to take it in the morning, as Sinclair does, though there is no strong evidence that timing significantly affects efficacy. Consistency in daily administration is advisable if supplementation is undertaken.

Formulation: Resveratrol supplements are available in various forms, including capsules, tablets, and powders. Trans-resveratrol is the active isomer and should be specified on the product label. Some formulations include additional ingredients such as piperine (from black pepper) or quercetin, which are claimed to enhance bioavailability, though clinical evidence for these combinations is limited.

Monitoring and follow-up: Patients should inform their GP if they begin taking resveratrol, particularly if they have pre-existing medical conditions or are on prescription medications. A pharmacist can provide advice on potential interactions. Routine monitoring is not typically required for healthy individuals, but those with diabetes, cardiovascular disease, or bleeding disorders should have closer medical oversight.

When to seek medical advice: Resveratrol is not recommended for those under 18, or during pregnancy or breastfeeding. Patients should contact their GP if they experience persistent gastrointestinal symptoms, unexplained bruising or bleeding, or any other concerning side effects. Seek urgent care for signs of severe allergic reaction (e.g., breathing difficulty, facial swelling). Resveratrol should not be used as a substitute for evidence-based treatments for any medical condition. Individuals with serious health concerns should prioritise conventional medical care and discuss any complementary approaches with their healthcare team.

Frequently Asked Questions